Although clinically meaningful activity was seen in HER2-null BC, the mPFS was 4.2 months in Cohort 3, compared to 6.7 months in HER2-low and 11.1 months in HER2-overexpressing cohorts. Here, ERBB2 is linked to breast cancer.